Dr. John Wallace, Antibe Therapeutics Founder and Chief Science Officer, Awarded the Heymans Foundation Memorial Medal
08 11월 2013 - 8:21AM
Business Wire
Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:
ATE) is proud to announce that Dr. John Wallace, the Corporation’s
Founder and Chief Science Officer, was awarded the Heymans
Foundation Memorial Medal in Ghent, Belgium, today. This
prestigious award, named after Corneille Heymans, a 1938 Nobel
Prize winner for Physiology/Medicine, has only been awarded 10
times since being established in 1972. Six of the previous winners
were Nobel Laureates.
Dr. Wallace received this honour based on his studies of
hydrogen sulfide as an endogenous anti-inflammatory, as well as the
development of new medicines based on those findings, through
Antibe Therapeutics.
For the last 20 years, Dr. Wallace's research has focused on
gaining a better understanding of the ulcers that can arise from
using painkillers and arthritis medications as well as of some the
most common digestive disorders, including irritable bowel
syndrome, ulcerative colitis, Crohn's disease, and colon
cancer.
About Antibe Therapeutics Inc.
Antibe Therapeutics Inc. originates, develops and out-licenses
patent-protected new pharmaceuticals that are improved
versions of existing drugs. These improvements are based on Nobel
Prize-winning medical research highlighting the crucial role
of gaseous mediators, chemical substances produced in the human
body to regulate a range of fundamental cellular processes.
The Corporation’s drug design methodologies involve chemically
linking an existing off-patent drug (“base drug”) to an
Antibe-patented, hydrogen sulfide-releasing molecule. For
medical conditions characterized by inflammation, pain or vascular
dysfunction, the Corporation’s methodologies can efficiently
produce improved versions of a number of existing drugs. Notably,
Antibe’s products are themselves fully patent-protectable and
may benefit from the predictable toxicity and
effectiveness profiles of the base drug.
www.antibethera.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Antibe Therapeutics Inc.Dan Legault, 416-473-4095Chief Executive
Officerdan.legault@antibethera.com
Antibe Therapeutics (TSXV:ATE)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Antibe Therapeutics (TSXV:ATE)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
